Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00038207 |
The goal of this clinical research study is to learn if treatment with the drug liposomal vincristine can shrink or slow the growth of the patient's cancer. The safety of this drug will also be studied.
Condition | Intervention | Phase |
---|---|---|
Soft Tissue Sarcoma Lymphoma Leukemia Wilms' Tumor Osteosarcoma |
Drug: Liposomal Vincristine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study |
Official Title: | Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with relapsed malignancies in the following strata: (As of 09/01/02, the soft tissue sarcoma strata will remain open for new patient accrual. Strata listed in b, c, d, e will be closed to entry).
Exclusion criteria:
Study ID Numbers: | P99-401 |
Study First Received: | May 29, 2002 |
Last Updated: | November 14, 2005 |
ClinicalTrials.gov Identifier: | NCT00038207 History of Changes |
Health Authority: | United States: Food and Drug Administration |
soft tissue sarcoma Bone sarcomas |
Urinary Tract Neoplasm Urogenital Neoplasms Urologic Neoplasms Leukemia Neoplasms, Connective and Soft Tissue Soft Tissue Sarcomas Renal Cancer Urologic Diseases Kidney Neoplasms Wilms' Tumor Wilms Tumor Osteogenic Sarcoma Kidney Diseases Lymphoma |
Kidney Cancer Immunoproliferative Disorders Osteosarcoma Vincristine Antimitotic Agents Lymphatic Diseases Malignant Mesenchymal Tumor Neoplastic Syndromes, Hereditary Genetic Diseases, Inborn Tubulin Modulators Sarcoma Lymphoproliferative Disorders Antineoplastic Agents, Phytogenic |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Urogenital Neoplasms Urologic Neoplasms Leukemia Neoplasms, Connective and Soft Tissue Neoplasms by Site Urologic Diseases Kidney Neoplasms Therapeutic Uses Wilms Tumor Kidney Diseases Lymphoma Immunoproliferative Disorders Neoplasms by Histologic Type |
Immune System Diseases Mitosis Modulators Osteosarcoma Vincristine Antimitotic Agents Pharmacologic Actions Lymphatic Diseases Neoplasms Neoplastic Syndromes, Hereditary Neoplasms, Bone Tissue Genetic Diseases, Inborn Tubulin Modulators Sarcoma Neoplasms, Connective Tissue Lymphoproliferative Disorders |